Prognostic relevance of urinary bladder cancer susceptibility loci

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Grotenhuis, Anne J ^a   Dudek, Aleksandra M ^a   Verhaegh, Gerald W ^a   Witjes, J Alfred ^a   Aben, Katja K ^a,b   Van Der Marel, Saskia L ^a   Vermeulen, Sita H ^a   Kiemeney, Lambertus A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Netherlands Comprehensive Cancer Organisation The Netherlands   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; CYSTECTOMY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUSCLE INVASIVE BLADDER CANCER; NETHERLANDS; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; BLADDER TUMOR; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 84897792278     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089164     Document Type: Article

References (48)

1. Sylvester RJ (2011) How well can you actually predict which non-muscle-invasive bladder cancer patients will progress? Eur Urol 60: 431-433; discussion 433-434.
2. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, et al. (2011) Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 60: 484-492.
3. van Rhijn BW (2012) Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer. Urol Oncol 30: 518-523.
4. Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, et al. (2010) Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol 28: 4029-4037.
5. O'Donnell PH, Ratain MJ (2012) Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol 6: 251-259.
6. Wang L, McLeod HL, Weinshilboum RM (2011) Genomics and drug response. N Engl J Med 364: 1144-1153.
7. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ (2013) Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet 14: 23-34.
8. Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, et al. (2010) Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila) 3: 1235-1245.
9. Ke HL, Chen M, Ye Y, Hildebrandt MA, Wu WJ, et al. (2013) Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer. Carcinogenesis 34: 1006-1011.
10. Chang DW, Gu J, Wu X (2012) Germline prognostic markers for urinary bladder cancer: obstacles and opportunities. Urol Oncol 30: 524-532.
11. Grotenhuis AJ, Vermeulen SH, Kiemeney LA (2010) Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response. Future Oncol 6: 1433-1460.
12. Gu J, Wu X (2011) Genetic susceptibility to bladder cancer risk and outcome. Per Med 8: 365-374.
13. Rafnar T, Vermeulen SH, Sulem P, Thorleifsson G, Aben KK, et al. (2011) European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet 20: 4268-4281.
14. Dai J, Gu J, Huang M, Eng C, Kopetz ES, et al. (2012) GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis 33: 1327-1331.
15. Fasching PA, Pharoah PD, Cox A, Nevanlinna H, Bojesen SE, et al. (2012) The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet 21: 3926-3939.
16. Gallagher DJ, Vijai J, Cronin AM, Bhatia J, Vickers AJ, et al. (2010) Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res 16: 2819-2832.
17. Rizzato C, Campa D, Giese N, Werner J, Rachakonda PS, et al. (2011) Pancreatic cancer susceptibility loci and their role in survival. PLoS One 6: e27921.
18. Shan J, Mahfoudh W, Dsouza SP, Hassen E, Bouaouina N, et al. (2012) Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians. Breast Cancer Res Treat 135: 715-724.
19. Xing J, Myers RE, He X, Qu F, Zhou F, et al. (2011) GWAS-identified colorectal cancer susceptibility locus associates with disease prognosis. Eur J Cancer 47: 1699-1707.
20. Xun WW, Brennan P, Tjonneland A, Vogel U, Overvad K, et al. (2011) Single-nucleotide polymorphisms (5p15.33, 15q25.1, 6p22.1, 6q27 and 7p15.3) and lung cancer survival in the European Prospective Investigation into Cancer and Nutrition (EPIC). Mutagenesis 26: 657-666.
21. Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, et al. (2010) A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 42: 415-419.
22. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, et al. (2009) Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 41: 221-227.
23. Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK, et al. (2008) Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 40: 1307-1312.
24. Garcia-Closas M, Hein DW, Silverman D, Malats N, Yeager M, et al. (2011) A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet Genomics 21: 231-236.
25. Fu YP, Kohaar I, Rothman N, Earl J, Figueroa JD, et al. (2012) Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. Proc Natl Acad Sci U S A 109: 4974-4979.
26. Tang W, Fu YP, Figueroa JD, Malats N, Garcia-Closas M, et al. (2012) Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. Hum Mol Genet 21: 1918-1930.
27. Aulchenko YS, Struchalin MV, van Duijn CM (2010) ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics 11: 1-10.
28. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, et al. (2010) LocusZoom: Regional visualization of genome-wide association scan results. Bioinformatics 26: 2336-2337.
29. Savas S, Liu G (2009) Genetic variations as cancer prognostic markers: review and update. Hum Mutat 30: 1369-1377.
30. Spitz MR, Wu X, Mills G (2005) Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 23: 267-275. (Pubitemid 46206878)
31. Cortessis VK, Yuan JM, Van Den Berg D, Jiang X, Gago-Dominguez M, et al. (2010) Risk of urinary bladder cancer is associated with 8q24 variant rs9642880[T] in multiple racial/ethnic groups: results from the Los Angeles-Shanghai case-control study. Cancer Epidemiol Biomarkers Prev 19: 3150-3156.
32. Golka K, Hermes M, Selinski S, Blaszkewicz M, Bolt HM, et al. (2009) Susceptibility to urinary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure. Pharmacogenet Genomics 19: 903-906.
33. Ma Z, Hu Q, Chen Z, Tao S, Macnamara L, et al. (2013) Systematic evaluation of bladder cancer risk-associated single-nucleotide polymorphisms in a Chinese population. Mol Carcinog 52: 916-921.
34. Wang M, Wang M, Zhang W, Yuan L, Fu G, et al. (2009) Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population. Carcinogenesis 30: 991-996.
35. Yates DR, Roupret M, Drouin SJ, Audouin M, Cancel-Tassin G, et al. (2013) Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours. World J Urol 31: 53-59.
36. Ahn J, Kibel AS, Park JY, Rebbeck TR, Rennert H, et al. (2011) Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res 17: 1075-1081.
37. Bertucci F, Lagarde A, Ferrari A, Finetti P, Charafe-Jauffret E, et al. (2012) 8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer. PLoS One 7: e37943.
38. Hoskins JM, Ong PS, Keku TO, Galanko JA, Martin CF, et al. (2012) Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome. PLoS One 7: e41954.
39. Suzuki M, Liu M, Kurosaki T, Suzuki M, Arai T, et al. (2011) Association of rs6983561 polymorphism at 8q24 with prostate cancer mortality in a Japanese population. Clin Genitourin Cancer 9: 46-52.
40. Takatsuno Y, Mimori K, Yamamoto K, Sato T, Niida A, et al. (2013) The rs6983267 SNP Is Associated with MYC Transcription Efficiency, Which Promotes Progression and Worsens Prognosis of Colorectal Cancer. Ann Surg Oncol 20: 1395-1402.
41. Zhang X, Chen Q, He C, Mao W, Zhang L, et al. (2012) Polymorphisms on 8q24 are associated with lung cancer risk and survival in Han Chinese. PLoS One 7: e41930.
42. Grisanzio C, Freedman ML (2010) Chromosome 8q24-Associated Cancers and MYC. Genes Cancer 1: 555-559.
43. Huppi K, Pitt JJ, Wahlberg BM, Caplen NJ (2012) The 8q24 gene desert: an oasis of non-coding transcriptional activity. Front Genet 3: 1-11.
44. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, et al. (2013) EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. Eur Urol 64: 639-653.
45. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, et al. (2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366: 649-659. (Pubitemid 41176017)
46. Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, et al. (2009) Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 41: 991-995.
47. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, et al. (2010) A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 42: 978-984.
48. Figueroa JD, Ye Y, Siddig A, Garcia-Closas M, Chatterjee N, et al. (2013) Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet doi:10.1093/hmg/ddt519.